Barclays raised the firm’s price target on Syndax Pharmaceuticals to $34 from $31 and keeps an Overweight rating on the shares. The analyst is “incrementally positive” around Syndax’s axatilimab in chronic graft versus host disease, seeing the drug’s response rate and duration of response as competitive with Sanofi’s Rezurock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SNDX: